LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

About this update from Lir Life Sciences Corp.

VANCOUVER, BC / ACCESS Newswire / June 17, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion of its comparative mouse study (the "Study") evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies1. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules. As previously reported, interim results from the Study demonstrated that a skin-applied protamine formulation of semaglutide could produce a meaningful reduction in blood glucose following an oral glucose challenge, approaching the glucose control profile observed with injectable administration. The final phase of the Study extended this same experimental framework to tirzepatide, a dual GLP-1/GIP receptor agonist, to assess whether similar skin permeability performance could be achieved with a second, structurally distinct incretin-based therapy. These results indicate that animals treated with a protamine-enabled topical formulation of tirzepatide exhibited glucose response profiles that were comparable to those observed with topical semaglutide, including blunting of post-challenge glucose excursions relative to untreated controls and sustained glucose stability over the observation period. Importantly, the magnitude and shape of the glucose-lowering response following skin permeation administration were closely aligned between the two molecules, supporting the reproducibility of the platform across multiple GLP/GIP-based therapies. The Study also compared topical protamine formulations of semaglutide and tirzepatide against standard subcutaneous injection and untreated controls using a standardized glucose tolerance model. Completion of the Study for both compounds demonstrated that the observed skin permeation activity may not be limited to a single drug, but instead likely reflects a broader, molecule-agnostic capability of the protamine delivery system. "These final results are important because they show consistency," said Edward Mills, CEO of LIR Life Sciences. "Seeing closely aligned skin permeation performance with both semaglutide and tirzepatide strengthens our confidence that this is a platform-level effect rather than ...

View stock analysis, news, and events for Lir Life Sciences Corp.